Shimadzu Journal vol.8 Issue1

Application Note No. 62 Analysis of Pharmaceuticals’ Impurity - Regulations and Analysis for Carcinogenic Substances Dheeraj Handique *a), Nitish Suryawanshi *a), Crystal Yeong *b), Cynthia Lahey *b), Shailendra Rane *a), Deepti Bhandarkar *a), Anant Lohar *a), Gao Jie san *c),…

Nitrosamine impurities analysis solution guide • Find the right analytical solution for each stage of nitrosamine impurity analysis • Confidently detect and quantify genotoxic impurities in active pharmaceutical ingredients and finished drug products Table of contents Monitoring genotoxic impurities in…

NDMA impurity in Ranitidine / LCMSTM-9030 Application News Detection and Quantitation of NDMA Impurity in Ranitidine Drug Substances and Products by LC-HRMS on LCMS-9030 Zhe Sun and Zhaoqi Zhan User Benefits  Determination of NDMA in ranitidine API and drug…

Nitrosamine Impurities Application Guide Confidently Detect and Quantify Mutagenic Impurities in APIs and Drug Products Sartan-Based Losartan Valsartan Candesartan Telmisartan Metformin Ranitidine Nitrosamines are formed by chemical reactions that occur during API manufacturing whether from starting materials, intermediates, reactants, reuse…